Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce Collaborative Research Grant Using Novel Gene Editing Technology to Address Root Cause of Friedreich’s Ataxia Disease
April 17, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, April 17, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Friedreich’s Ataxia Research Alliance (FARA) announced today a collaborative grant for $300,000 awarded to...
Muscular Dystrophy Association Celebrates FDA Approval of Skyclarys, First Ever Treatment for Friedreich’s Ataxia from Reata Pharmaceuticals
February 28, 2023 20:18 ET
|
Muscular Dystrophy Association
New York, NY, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Omaveloxolone (Skyclarys), the first ever...
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
February 11, 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
The Friedreich’s Ataxia Research Alliance Hires Barbara Tate, Ph.D. as FARA's New Chief Scientific Officer
May 27, 2020 09:00 ET
|
Friedreich's Ataxia Research Alliance
DOWNINGTOWN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA) today announced the hiring of Barbara Tate, Ph.D. to the full-time role...
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
January 09, 2020 10:24 ET
|
Retrotope
LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...
The Friedreich’s Ataxia Research Alliance Promotes Jennifer Farmer, MS to Chief Executive Officer
December 05, 2019 15:00 ET
|
Friedreich's Ataxia Research Alliance
DOWNINGTOWN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- The Board of Directors at The Friedreich’s Ataxia Research Alliance (FARA) today announced the promotion of Jennifer Farmer, MS to the role of...
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
July 19, 2019 11:15 ET
|
Retrotope
LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
January 29, 2019 07:00 ET
|
Voyager Therapeutics, Inc.; Neurocrine Biosciences, Inc.
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains...
Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 18, 2018 18:30 ET
|
Voyager Therapeutics, Inc.
Voyager’s gene therapy vector for Friedreich’s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration Durable safety data...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
November 02, 2017 09:00 ET
|
Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...